LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Biotechnology?src=hash" target="_blank"gt;#Biotechnologylt;/agt;–The global cervical cancer therapeutics market is expected to post a
CAGR of close to 7% during the period 2019-2023, according to the latest
market research report by Technavio.
A key factor driving the growth of the global cervical cancer
therapeutics market is the increasing female health initiatives. The
growing prevalence of various female health conditions has become one of
the delicate concerns across the world. There has been a significant
rise in the number of females affected with several oncology indications
such as breast cancer and gynecological cancers, which includes cervical
cancer. As a result, various female health initiatives are being carried
out by several organizations including non-government organizations
(NGOs). For instance, the American Cancer Society runs a National Breast
and Cervical Cancer Early Detection Program (NBCCEDP). Such initiatives
and programs allow female patients to discuss their problems with the
concerned professionals and avail necessary treatment, thereby driving
the market growth.
As per Technavio, the development of T-cell immunotherapy will have a
positive impact on the market and contribute to its growth significantly
over the forecast period. This global
cervical cancer therapeutics market 2019-2023 research
report also analyzes other important trends and market drivers that will
affect market growth over 2019-2023.
Global cervical cancer therapeutics market:
Development of T-cell immunotherapy
The treatment available for cervical cancer currently includes
chemotherapy and biologics such as vaccines and monoclonal antibodies.
However, there are only a few biologics that are approved for the
treatment of cervical cancer, which offers a huge opportunity for other
effective treatment options such as adoptive T-cell therapy (ACT) and
autologous tumor infiltrating lymphocytes (TIL). T-cell-based
immunotherapy is gaining significant traction and is playing a pivotal
role in the diagnosis of cervical cancer. T-cell-based immunotherapy is
more specific and is entitled with broader therapeutic potential for
“Apart from the increasing female health initiatives and the
development of T-cell immunotherapy, factors such as the advancements in
diagnostics, growing popularity of targeted therapies, advent of
vaccines, and strategic alliances will have a significant impact on the
growth of the cervical cancer therapeutics market during the forecast
period,” says a senior research analyst at Technavio.
Global cervical cancer therapeutics market:
This market research report segments the global cervical cancer
therapeutics market by type (drugs and vaccines) and geographic regions
(North America, Europe, Asia, and ROW).
The North American region led the market in 2018, followed by Europe,
Asia, and ROW respectively. The US, the world’s largest pharmaceutical
market, is contributing significantly to the growth of the cervical
cancer therapeutics market in the region, in terms of technology as well
as the launch of new drugs and diagnostic tools. The market growth in
North America can be attributed to the high prevalence of cervical
cancer, advancements in diagnosis, and government initiatives that aim
at preventing and controlling gynecological cancer in the region.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at [email protected].
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200